Prostate‐specific membrane antigen theranostics in advanced prostate cancer: an evolving option

Objectives To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer. Methods Narrative review focussing on PSMA as a target for RLT, and data using Results RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate‐resistant prostate cancer (mCRPC). To date, most evidence exists regarding small‐molecule PSMA inhibitors bound to beta‐emitting radioisotopes such as 177Lu (Lu‐PSMA). Prospective phase II data supports the safety and efficacy of Lu‐PSMA in men with heavily pre‐treated progressive mCRPC, and several late‐phase randomised trials of Lu‐PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states. Conclusions PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.